FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157210004> ?p ?o ?g. }

• W2157210004 endingPage "1286" @default.
• W2157210004 startingPage "1279" @default.
• W2157210004 abstract "To evaluate computed tomography (CT)-guided brachytherapy in patients with very large liver malignancies or with liver tumors located adjacent to the liver hilum.In this prospective nonrandomized phase II trial, we treated 20 patients (19 liver metastases and one cholangiocarcinoma) with CT-guided high-dose-rate (HDR) brachytherapy using a (192) Iridium source. All patients demonstrated no functional liver degradation prior to irradiation. Entry criteria were liver tumors > 5 cm (group A, n = 11, no upper limit) or liver tumors < or = 5 cm adjacent to the liver hilum (group B, n = 9). Dose planning for brachytherapy was performed with three dimensional (3D) CT data acquired after percutaneous applicator positioning. Magnetic resonance (MR) imaging follow-up was performed 6 weeks and every 3 months post intervention. Primary endpoints were complications, local tumor control (absence of tumor growth after treatment followed by shrinkage of the lesion starting at 6 months) and progression-free survival.The mean tumor diameter was 7.7 cm (range, 5.5-10.8 cm) in group A, 3.6 cm (range, 2.2-4.9 cm) in group B. On average, a minimal dose of 17 Gy in the target volume was applied (range, 12-25 Gy). Severe side effects were recorded in two patients (10%). One patient demonstrated an obstructive jaundice caused by tumor edema after irradiation of a metastasis adjacent to the bile duct bifurcation. One patient developed intra-abdominal hemorrhage that was treated by a single blood transfusion and has ceased. We frequently encountered moderate increases of liver enzymes (70% of patients) and bilirubin (50% of patients) without clinical symptoms and thus considered to be insignificant. The median follow-up was 13 months. In group A (tumors > 5 cm), primary local tumor control after 6 and 12 months was 74% and 40%, respectively; in group B, it was 100% and 71%, respectively. All but one local recurrence (in a patient with diffuse tumor progression) were successfully treated during another CT-guided brachytherapy leading to a primary assisted local control of 93% after 12 months.CT-guided brachytherapy based on individual dose plans and 3D CT data sets generated encouraging results in large liver malignancies as well as in tumors located adjacent to the liver hilum." @default.
• W2157210004 created "2016-06-24" @default.
• W2157210004 creator A5018154025 @default.
• W2157210004 creator A5021222763 @default.
• W2157210004 creator A5025926980 @default.
• W2157210004 creator A5032695553 @default.
• W2157210004 creator A5035134031 @default.
• W2157210004 creator A5040115020 @default.
• W2157210004 creator A5046852939 @default.
• W2157210004 creator A5055630389 @default.
• W2157210004 creator A5057055167 @default.
• W2157210004 creator A5057556136 @default.
• W2157210004 creator A5057700552 @default.
• W2157210004 creator A5089915345 @default.
• W2157210004 date "2004-11-01" @default.
• W2157210004 modified "2023-10-16" @default.
• W2157210004 title "Liver Malignancies: CT-Guided Interstitial Brachytherapy in Patients with Unfavorable Lesions for Thermal Ablation" @default.
• W2157210004 cites W1543626870 @default.
• W2157210004 cites W1848028493 @default.
• W2157210004 cites W1966463781 @default.
• W2157210004 cites W1968439009 @default.
• W2157210004 cites W1969832670 @default.
• W2157210004 cites W1979800982 @default.
• W2157210004 cites W1995944130 @default.
• W2157210004 cites W2004673269 @default.
• W2157210004 cites W2008114626 @default.
• W2157210004 cites W2019776433 @default.
• W2157210004 cites W2022326226 @default.
• W2157210004 cites W2024028163 @default.
• W2157210004 cites W2036028589 @default.
• W2157210004 cites W2037899459 @default.
• W2157210004 cites W2037984373 @default.
• W2157210004 cites W2040040359 @default.
• W2157210004 cites W2069506836 @default.
• W2157210004 cites W2077645480 @default.
• W2157210004 cites W2079686554 @default.
• W2157210004 cites W2081354741 @default.
• W2157210004 cites W2084905853 @default.
• W2157210004 cites W2088489276 @default.
• W2157210004 cites W2111910408 @default.
• W2157210004 cites W2127662599 @default.
• W2157210004 cites W2130814380 @default.
• W2157210004 cites W2146636675 @default.
• W2157210004 cites W2148045478 @default.
• W2157210004 cites W2157416388 @default.
• W2157210004 cites W2616250578 @default.
• W2157210004 cites W4243924294 @default.
• W2157210004 doi "https://doi.org/10.1097/01.rvi.0000141343.43441.06" @default.
• W2157210004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15525748" @default.
• W2157210004 hasPublicationYear "2004" @default.
• W2157210004 type Work @default.
• W2157210004 sameAs 2157210004 @default.
• W2157210004 citedByCount "102" @default.
• W2157210004 countsByYear W21572100042012 @default.
• W2157210004 countsByYear W21572100042013 @default.
• W2157210004 countsByYear W21572100042014 @default.
• W2157210004 countsByYear W21572100042015 @default.
• W2157210004 countsByYear W21572100042016 @default.
• W2157210004 countsByYear W21572100042017 @default.
• W2157210004 countsByYear W21572100042018 @default.
• W2157210004 countsByYear W21572100042019 @default.
• W2157210004 countsByYear W21572100042020 @default.
• W2157210004 countsByYear W21572100042021 @default.
• W2157210004 countsByYear W21572100042022 @default.
• W2157210004 countsByYear W21572100042023 @default.
• W2157210004 crossrefType "journal-article" @default.
• W2157210004 hasAuthorship W2157210004A5018154025 @default.
• W2157210004 hasAuthorship W2157210004A5021222763 @default.
• W2157210004 hasAuthorship W2157210004A5025926980 @default.
• W2157210004 hasAuthorship W2157210004A5032695553 @default.
• W2157210004 hasAuthorship W2157210004A5035134031 @default.
• W2157210004 hasAuthorship W2157210004A5040115020 @default.
• W2157210004 hasAuthorship W2157210004A5046852939 @default.
• W2157210004 hasAuthorship W2157210004A5055630389 @default.
• W2157210004 hasAuthorship W2157210004A5057055167 @default.
• W2157210004 hasAuthorship W2157210004A5057556136 @default.
• W2157210004 hasAuthorship W2157210004A5057700552 @default.
• W2157210004 hasAuthorship W2157210004A5089915345 @default.
• W2157210004 hasConcept C121608353 @default.
• W2157210004 hasConcept C126322002 @default.
• W2157210004 hasConcept C126838900 @default.
• W2157210004 hasConcept C2777416452 @default.
• W2157210004 hasConcept C2779013556 @default.
• W2157210004 hasConcept C2779819216 @default.
• W2157210004 hasConcept C2989005 @default.
• W2157210004 hasConcept C509974204 @default.
• W2157210004 hasConcept C71924100 @default.
• W2157210004 hasConceptScore W2157210004C121608353 @default.
• W2157210004 hasConceptScore W2157210004C126322002 @default.
• W2157210004 hasConceptScore W2157210004C126838900 @default.
• W2157210004 hasConceptScore W2157210004C2777416452 @default.
• W2157210004 hasConceptScore W2157210004C2779013556 @default.
• W2157210004 hasConceptScore W2157210004C2779819216 @default.
• W2157210004 hasConceptScore W2157210004C2989005 @default.
• W2157210004 hasConceptScore W2157210004C509974204 @default.
• W2157210004 hasConceptScore W2157210004C71924100 @default.
• W2157210004 hasIssue "11" @default.
• W2157210004 hasLocation W21572100041 @default.

• next